This page was translated automatically from Turkish. Read the original

Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun.

EV1123

Adjunctive lumateperone in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials

ADJUNCTIVE LUMATEPERONE FOR MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

In a pooled analysis of three randomized controlled trials, adjunctive lumateperone did not demonstrate statistically significant superiority over placebo in response or remission.

The objective was to evaluate the efficacy of adjunctive lumateperone versus placebo in adults with major depressive disorder (MDD). PubMed, Embase, and the Cochrane Library were searched, and randomized controlled trials reporting response and remission at the acute endpoint were included. Analyses were performed using RevMan 5.4, and heterogeneity was assessed using the I² statistic; response was defined as a reduction of at least 50% from baseline on each study's primary clinician-rated depression scale. Three randomized controlled trials involving a total of 1,008 participants were analyzed; 501 patients (49.7%) received adjunctive lumateperone, follow-up ranged from 6 to 8 weeks, mean age ranged from 36.9 to 46 years, and 34.4% of participants were male. In the pooled analysis, the risk ratio (RR) for response was 1.52 (95% confidence interval 0.86–2.69; p=0.09; I²=75%), and the RR for remission was 1.63 (95% confidence interval 0.89–3.01; p=0.07; I²=34%); neither reached statistical significance. Individual studies reported results favoring lumateperone (Durgam et al. 2025a, RR 1.90; Durgam et al. 2025b, RR 1.58; Hosseinnia et al. 2026, RR 1.21, for response). In conclusion, despite the positive findings in individual studies, the pooled data do not support definitive clinical superiority; this may be related to the limited sample size and between-study heterogeneity. Adequately powered, high-quality randomized trials are needed to clarify the role of lumateperone as an adjunctive treatment in patients with MDD who have a partial response to antidepressant treatment.

Tüm WCP 2026 özetleri